P/E của cổ phiếu IRWD là bao nhiêu?

IRONWOOD PHARMACEUTICALS INC (IRWD) hiện giao dịch ở mức P/E 6.01 lần.

ROE của cổ phiếu IRWD là bao nhiêu?

IRONWOOD PHARMACEUTICALS INC có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) -47.05%.

Tỷ suất cổ tức của IRWD là bao nhiêu?

IRONWOOD PHARMACEUTICALS INC có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của IRWD là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của IRWD ở mức 69/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu IRWD không?

Điểm AI Timing của IRWD là 56/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu IRWD thuộc ngành nào?

IRONWOOD PHARMACEUTICALS INC được xếp vào ngành Healthcare >> Drug Manufacturers - Specialty & Generic trên sàn NASDAQ

Cổ phiếu IRWD (NASDAQ) | IRONWOOD PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

IRWD AI Analysis Summary

Our AI summary for IRWD: IRONWOOD PHARMACEUTICALS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 6.01, ROE of -47.05%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

IRWD

IRONWOOD PHARMACEUTICALS INC

USD 4.23

0.50 (13.40%) Day Change

Watchlist Portfolio Compare Chart

6.01

P/E

-2.71

D/E

-47.1%

ROE

23.5%

ROA

0.00%

Div Yield

0.01

PEG

IRONWOOD PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.23 Price 0.50 (13.40%) Day Change	NEWS SCORE: 99

IRWD Chất lượng tổng thể của cố phiếu Khá ( Chất lượng = 69) và Thời điểm mua ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Tỷ lệ ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROE đang giảm đáng kể
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Khá , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

63%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	430
Magic Formula Rank by ROE	430
Magic Formula Rank by ROIC	109
Price	4.23
PBV / Sector	-2.83 / 3.22
Earning Per Share	0.70

PE / Sector	6.01 / 29.79 GREAT
PEG or PE/Growth / Sector	0.01 / 0.13 GREAT
Average 1M Daily Value	9.01 M
Average 1W Daily Value	7.79 M

Yếu tố Kỹ thuật

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	28.26 / 15.21 GREAT
NPM Average (%) / Sector	-29.42 / -10.83
NPM Change Average (%) / Sector	663.98 / 117.42 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	23.51 / 8.15 GOOD
ROA Average (%) / Sector	-33.41 / 2.87
ROA Change Average (%) / Sector	265.98 / 112.70 GREAT
ROE (%) / Sector	-47.05 / -1.02
ROE Average (%) / Sector	51.95 / 8.35 GREAT
ROE Change Average (%) / Sector	1,083.08 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:02
Symbol	IRWD
Name	IRONWOOD PHARMACEUTICALS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	164.61 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	614.01 / 10,754.62

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 100 Summer Street, Boston, MA, United States, 02110

Phone: 617 621 7722

Website: https://ironwoodpharma.com

Employees: 100

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.